ATE366582T1 - Optimierte minigene und dadurch kodierte peptide - Google Patents

Optimierte minigene und dadurch kodierte peptide

Info

Publication number
ATE366582T1
ATE366582T1 AT00989585T AT00989585T ATE366582T1 AT E366582 T1 ATE366582 T1 AT E366582T1 AT 00989585 T AT00989585 T AT 00989585T AT 00989585 T AT00989585 T AT 00989585T AT E366582 T1 ATE366582 T1 AT E366582T1
Authority
AT
Austria
Prior art keywords
peptides encoded
vaccines
optimized
minigenes
optimized minigenes
Prior art date
Application number
AT00989585T
Other languages
English (en)
Inventor
Alessandro Sette
Robert Chesnut
Brian Livingston
Denise Baker
Mark Newman
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Application granted granted Critical
Publication of ATE366582T1 publication Critical patent/ATE366582T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AT00989585T 1999-12-28 2000-12-28 Optimierte minigene und dadurch kodierte peptide ATE366582T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17339099P 1999-12-28 1999-12-28

Publications (1)

Publication Number Publication Date
ATE366582T1 true ATE366582T1 (de) 2007-08-15

Family

ID=22631795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00989585T ATE366582T1 (de) 1999-12-28 2000-12-28 Optimierte minigene und dadurch kodierte peptide

Country Status (14)

Country Link
EP (1) EP1242108B1 (de)
JP (2) JP2004512815A (de)
KR (1) KR100838507B1 (de)
CN (1) CN1437476A (de)
AT (1) ATE366582T1 (de)
AU (1) AU780064B2 (de)
BR (1) BR0017052B1 (de)
CA (1) CA2394748A1 (de)
DE (1) DE60035523T2 (de)
DK (1) DK1242108T3 (de)
ES (1) ES2288885T3 (de)
HK (1) HK1048068B (de)
MX (1) MXPA02006554A (de)
WO (1) WO2001047541A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
CA2500955A1 (en) * 2002-10-03 2004-04-15 Genencor International, Inc. Optimized multi-epitope constructs and uses thereof
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005047483A2 (en) * 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2909238A4 (de) 2012-10-19 2016-11-30 Queensland Inst Med Res Verbesserte immuntherapie gegen das humane herpesvirus
EP3417874B1 (de) 2012-11-28 2024-09-11 BioNTech SE Individualisierte impfstoffe gegen krebs
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105254719B (zh) * 2015-10-21 2018-07-13 黑龙江八一农垦大学 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
EP3634449A4 (de) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. Alphavirus-neoantigen-vektoren
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7314441B2 (ja) * 2018-01-22 2023-07-26 国立感染症研究所長 選択的ｃｄ８陽性ｔ細胞誘導ワクチン抗原
AU2019275072A1 (en) * 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0769963A4 (de) * 1994-07-27 1999-07-28 Commw Scient Ind Res Org Polyepitope impfstoffe
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
NZ333431A (en) * 1996-05-24 2000-05-26 Chiron Corp Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
KR100838507B1 (ko) 2008-06-17
AU2607501A (en) 2001-07-09
BR0017052B1 (pt) 2013-12-24
ES2288885T3 (es) 2008-02-01
WO2001047541A1 (en) 2001-07-05
MXPA02006554A (es) 2003-09-22
EP1242108B1 (de) 2007-07-11
DK1242108T3 (da) 2007-11-12
EP1242108A4 (de) 2005-11-02
HK1048068A1 (en) 2003-03-21
AU780064B2 (en) 2005-02-24
JP5628716B2 (ja) 2014-11-19
JP2004512815A (ja) 2004-04-30
EP1242108A1 (de) 2002-09-25
CA2394748A1 (en) 2001-07-05
DE60035523D1 (de) 2007-08-23
DE60035523T2 (de) 2008-03-20
CN1437476A (zh) 2003-08-20
KR20020084424A (ko) 2002-11-07
BR0017052A (pt) 2006-03-01
JP2011168592A (ja) 2011-09-01
HK1048068B (en) 2008-02-22

Similar Documents

Publication Publication Date Title
ATE366582T1 (de) Optimierte minigene und dadurch kodierte peptide
CY1119106T1 (el) Αντισωματα εναντι masp-2
AU2003296330A8 (en) Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
IL210378A0 (en) Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines
CY1116149T1 (el) Αντισωματα anti-tnf, συνθεσεις, μεθοδοι και χρησεις αυτων
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2005007673A3 (en) Immunogenic peptides
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
PT1290160E (pt) Polipeptideos pellino humanos
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
ATE466879T1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
WO2005033265A3 (en) Optimized multi-epitope constructs and uses thereof
WO2004053117A3 (en) Serine protease
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form